Mar 17 2010
Agilent Technologies Inc. (NYSE:A) today announced the availability of
new ion
exchange and size exclusion columns specifically designed for the
analysis of bio-molecules including monoclonal antibodies, recombinant
proteins, peptides, vaccine products and DNA/RNA. The columns provide
robust, reproducible and high-resolution solutions for biopharmaceutical
manufacturers to effectively monitor the safety, efficacy and stability
of their products.
“The new columns greatly expand our current bio-columns
portfolio, which also include reverse phase columns for intact protein
separations and peptide mapping.”
“With the addition of these new bio-columns, we can now offer our
customers significant improvements in charge-based and size-based
analytical separations of bio-molecules,” said Helen Stimson, vice
president and general manager of Agilent’s Consumables and Supplies
Division. “The new columns greatly expand our current bio-columns
portfolio, which also include reverse phase columns for intact protein
separations and peptide mapping.”
Each new column is individually tested with protein samples to ensure
column-to-column and batch-to-batch reproducibility. The four new column
families and their benefits include:
-
Agilent
Bio SEC-3 size exclusion columns, packed with a robust 3µm
particle, which offers higher resolution and faster separation times,
specifically for the analysis of monoclonal antibody aggregates;
-
Agilent
Bio SEC-5 size exclusion columns, packed with 5μm particles coated
with a neutral, hydrophilic coating, making the particle extremely
stable under harsh buffer conditions;
-
Agilent
Bio MAb columns, featuring a weak cation exchange (WCX) resin
specifically designed for high-resolution separations of monoclonal
antibody charge variants; and
-
Agilent
Bio IEX columns, designed for high-resolution, high-recovery and
highly efficient separations of proteins, peptides, oligonucleotides
and other bio-molecules.
Size exclusion chromatography is commonly used for the analysis of
protein aggregation when proteins bind together to form a larger
complex. Ion exchange chromatography is regularly used to monitor the
reproducibility of protein manufacturing. Charge variants are carefully
monitored, specifically glycosylation and deamidation, to ensure safety
and efficacy. Additional information about the new Agilent BioHPLC
columns is available at www.agilent.com/chem/biohplc.
Source Agilent Technologies